2016 Updates to the WHO Brain Tumor Classification System: What the Radiologist Needs to Know
- 1 November 2017
- journal article
- review article
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 37 (7), 2164-2180
- https://doi.org/10.1148/rg.2017170037
Abstract
In 2016, the World Health Organization updated its classification system for brain tumors, making a number of changes pertinent to radiologists, including the elimination or redefinition of previously recognized tumors (eg, oligoastrocytoma, gliomatosis cerebri), the addition of new tumors (eg, diffuse leptomeningeal glioneuronal tumor), and the incorporation of genetic factors into the definitions of infiltrating gliomas. Radiologists play a key role in brain tumor diagnosis and management and must stay abreast of developments in the field to advance patient care and communicate with other health care providers. In 2016, the World Health Organization (WHO) released an update to its brain tumor classification system that included numerous significant changes. Several previously recognized brain tumor diagnoses, such as oligoastrocytoma, primitive neuroectodermal tumor, and gliomatosis cerebri, were redefined or eliminated altogether. Conversely, multiple new entities were recognized, including diffuse leptomeningeal glioneuronal tumor and multinodular and vacuolating tumor of the cerebrum. The glioma category has been significantly reorganized, with several infiltrating gliomas in children and adults now defined by genetic features for the first time. These changes were driven by increased understanding of important genetic factors that directly impact tumorigenesis and influence patient care. The increased emphasis on gene...This publication has 69 references indexed in Scilit:
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summaryActa Neuropathologica, 2016
- Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade GliomaThe New England Journal of Medicine, 2016
- International Society of Neuropathology‐Haarlem Consensus Guidelines for Nervous System Tumor Classification and GradingBrain Pathology, 2014
- Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation ofIDHJournal of Clinical Oncology, 2014
- Molecular neuro-oncology in clinical practice: a new horizonThe Lancet Oncology, 2013
- Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951Journal of Clinical Oncology, 2013
- Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopyJournal of Neuro-Oncology, 2011
- Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomasActa Neuropathologica, 2010
- IDH1andIDH2Mutations in GliomasThe New England Journal of Medicine, 2009
- MGMTGene Silencing and Benefit from Temozolomide in GlioblastomaThe New England Journal of Medicine, 2005